Company intelligence / Profile preview

Engage Therapeutics

Summit, New Jersey, United States

Ownership: Private
Employees: ~1
Development stage: Phase 2

Overview

Engage Therapeutics was developing Staccato Alprazolam, an investigational drug designed as a single-use epileptic seizure rescue therapy that combines the Staccato delivery technology with alprazolam, a benzodiazepine. The company was acquired by UCB in 2020 during Phase 2 development.

Therapeutic areas: Neurology
Modalities: Small molecules (Alprazolam)
Industry: Biotech

Drug pipeline

1 asset

alprazolam

Phase 2

Indications: Epilepsy, Acute seizures

Partnerships

Alexza Pharmaceuticals Inc. (license agreement for Staccato technology)

Beyond the preview

Go deeper on Engage Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Engage Therapeutics.

Explore the full profile